Will the Phase 2 trial "Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer" reach primary completion on or before Jan 10, 2027?

Resolves Yes if ClinicalTrials.gov record NCT06207734 (Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest) shows an actual primary completion date on or before Jan 10, 2027. Registered date at generation: Jan 10, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Jan 10, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.